These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 19490111

  • 21. Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor.
    Petersen LC, Olsen OH, Nielsen LS, Freskgård PO, Persson E.
    Protein Sci; 2000 May; 9(5):859-66. PubMed ID: 10850795
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain.
    Ruf W, Shobe J, Rao SM, Dickinson CD, Olson A, Edgington TS.
    Biochemistry; 1999 Feb 16; 38(7):1957-66. PubMed ID: 10026279
    [Abstract] [Full Text] [Related]

  • 24. Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa.
    Yang J, Lee GF, Riederer MA, Kelley RF.
    Thromb Haemost; 2002 Mar 16; 87(3):450-8. PubMed ID: 11916078
    [Abstract] [Full Text] [Related]

  • 25. Evolutionary conservation of the allosteric activation of factor VIIa by tissue factor in lamprey.
    Beeler DL, Aird WC, Grant MA.
    J Thromb Haemost; 2018 Apr 16; 16(4):734-748. PubMed ID: 29418058
    [Abstract] [Full Text] [Related]

  • 26. Molecular determinants involved in differential behaviour between soluble tissue factor and full-length tissue factor towards factor VIIa.
    Prasad R, Sen P.
    Phys Chem Chem Phys; 2017 Aug 23; 19(33):22230-22242. PubMed ID: 28799584
    [Abstract] [Full Text] [Related]

  • 27. Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity.
    Sorensen AB, Madsen JJ, Svensson LA, Pedersen AA, Østergaard H, Overgaard MT, Olsen OH, Gandhi PS.
    J Biol Chem; 2016 Feb 26; 291(9):4671-83. PubMed ID: 26694616
    [Abstract] [Full Text] [Related]

  • 28. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
    Iakhiaev A, Ruf W, Rao LV.
    Thromb Haemost; 2001 Mar 26; 85(3):458-63. PubMed ID: 11307815
    [Abstract] [Full Text] [Related]

  • 29. Tissue factor activates allosteric networks in factor VIIa through structural and dynamic changes.
    Madsen JJ, Persson E, Olsen OH.
    J Thromb Haemost; 2015 Feb 26; 13(2):262-7. PubMed ID: 25403348
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Interaction of activated factor VII and active site-inhibited activated factor VII with tissue factor.
    Sørensen BB, Rao LV.
    Blood Coagul Fibrinolysis; 1998 Mar 26; 9 Suppl 1():S67-71. PubMed ID: 9819031
    [Abstract] [Full Text] [Related]

  • 32. Extensive small-angle X-ray scattering studies of blood coagulation factor VIIa reveal interdomain flexibility.
    Mosbaek CR, Nolan D, Persson E, Svergun DI, Bukrinsky JT, Vestergaard B.
    Biochemistry; 2010 Nov 16; 49(45):9739-45. PubMed ID: 20873866
    [Abstract] [Full Text] [Related]

  • 33. Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity.
    Jin J, Chang J, Chang JY, Kelley RF, Stafford DW, Straight DL.
    Biochemistry; 1999 Jan 26; 38(4):1185-92. PubMed ID: 9930978
    [Abstract] [Full Text] [Related]

  • 34. Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor.
    Persson E, Nielsen LS, Olsen OH.
    Biochemistry; 2001 Mar 20; 40(11):3251-6. PubMed ID: 11258943
    [Abstract] [Full Text] [Related]

  • 35. Model of a ternary complex between activated factor VII, tissue factor and factor IX.
    Chen SW, Pellequer JL, Schved JF, Giansily-Blaizot M.
    Thromb Haemost; 2002 Jul 20; 88(1):74-82. PubMed ID: 12152682
    [Abstract] [Full Text] [Related]

  • 36. Novel interactions of large P3 moiety and small P4 moiety in the binding of the peptide mimetic factor VIIa inhibitor.
    Kadono S, Sakamoto A, Kikuchi Y, Oh-Eda M, Yabuta N, Yoshihashi K, Kitazawa T, Suzuki T, Koga T, Hattori K, Shiraishi T, Haramura M, Kodama H, Ono Y, Esaki T, Sato H, Watanabe Y, Itoh S, Ohta M, Kozono T.
    Biochem Biophys Res Commun; 2005 Jan 28; 326(4):859-65. PubMed ID: 15607748
    [Abstract] [Full Text] [Related]

  • 37. The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry.
    Rand KD, Andersen MD, Olsen OH, Jørgensen TJ, Ostergaard H, Jensen ON, Stennicke HR, Persson E.
    J Biol Chem; 2008 May 09; 283(19):13378-87. PubMed ID: 18343822
    [Abstract] [Full Text] [Related]

  • 38. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.
    Zhong D, Bajaj MS, Schmidt AE, Bajaj SP.
    J Biol Chem; 2002 Feb 01; 277(5):3622-31. PubMed ID: 11723140
    [Abstract] [Full Text] [Related]

  • 39. Current status on tissue factor activation of factor VIIa.
    Persson E, Olsen OH.
    Thromb Res; 2010 Apr 01; 125 Suppl 1():S11-2. PubMed ID: 20153879
    [Abstract] [Full Text] [Related]

  • 40. Structural modulation of factor VIIa by full-length tissue factor (TF1-263): implication of novel interactions between EGF2 domain and TF.
    Prasad R, Sen P.
    J Biomol Struct Dyn; 2018 Feb 01; 36(3):621-633. PubMed ID: 28150568
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.